Mavoglurant

Mavoglurant (AFQ-056) is an experimental drug candidate for the treatment of fragile X syndrome. It exerts its effect as an antagonist of the metabotropic glutamate receptor 5 (mGLU5).

Mavoglurant is under development by Novartis and is currently in Phase II and Phase III clinical trials. If successful, it would be the first drug to treat the underlying disorder instead of the symptoms of fragile X syndrome.